Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 11—November 2006
Dispatch

VEB-1 in Achromobacter xylosoxidans from Cystic Fibrosis Patient, France

Catherine Neuwirth*Comments to Author , Carine Freby*, Agathe Ogier-Desserrey*, Stéphanie Perez-Martin*, Anne Houzel*, André Péchinot*, Jean-Marie Duez*, Fréderic Huet*, and Eliane Siebor*
Author affiliations: *Hôpital Universitaire du Bocage, Dijon, France

Main Article

Figure

A) Oval indicates area of synergy between ticarcillin (TIC) and TIC plus clavulanic acid (CA). B) Arrows point to inhibition zone around third-generation disks with and without CA. AMX, amoxicillin; FEP, cefepime; CAZ, ceftazidime; CTX, cefotaxime; CF, cefalotin.

Figure. A) Oval indicates area of synergy between ticarcillin (TIC) and TIC plus clavulanic acid (CA). B) Arrows point to inhibition zone around third-generation disks with and without CA. AMX, amoxicillin; FEP, cefepime; CAZ, ceftazidime; CTX, cefotaxime; CF, cefalotin.

Main Article

Page created: October 14, 2011
Page updated: October 14, 2011
Page reviewed: October 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external